Trial Profile
A Phase II Study of SI-613 in Patients with Knee Osteoarthritis (repeat-dose study)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 08 Oct 2020
Price :
$35
*
At a glance
- Drugs Diclofenac-Eatlhyaluronate (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Seikagaku Corporation
- 02 Oct 2020 Primary endpoint has been met. (Change from baseline in daily pain score)
- 02 Oct 2020 Primary endpoint has been met. (Change from baseline in WOMAC 3.1 Index (Pain) during 12 weeks)
- 02 Oct 2020 Primary endpoint has not been met. (Change from baseline in 50-foot walk test during 12 weeks)